Hugo Brugiere - Neovacs SA GM Chairman
| ALNEV Stock | EUR 0.0002 0.00 0.00% |
Insider
Hugo Brugiere is GM Chairman of Neovacs SA
| Phone | 33 1 53 10 93 00 |
| Web | https://www.neovacs.com |
Neovacs SA Management Efficiency
The company has return on total asset (ROA) of (0.113) % which means that it has lost $0.113 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2668) %, meaning that it generated substantial loss on money invested by shareholders. Neovacs SA's management efficiency ratios could be used to measure how well Neovacs SA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Philippe Sumeire | SEB SA | 61 | |
| Giles Pelissier | SEB SA | N/A | |
| Sylvain Morgeau | Biomerieux SA | N/A | |
| Cathy Pianon | SEB SA | N/A | |
| Valerie Leylde | Biomerieux SA | N/A | |
| Gilles Martin | Eurofins Scientific SE | 60 | |
| Alexandre Merieux | Biomerieux SA | 49 | |
| Delphine Vaylet | SEB SA | 53 | |
| Pierre Charbonnier | Biomerieux SA | N/A | |
| Laurent Lebras | Eurofins Scientific SE | N/A | |
| Nathalie Lomon | SEB SA | 52 | |
| Sandra Hoeylaerts | Eurofins Scientific SE | N/A | |
| David Bryant | Eurofins Scientific SE | N/A | |
| Yvoine Remy | Eurofins Scientific SE | N/A | |
| Benedikt Orzelek | Sartorius Stedim Biotech | N/A | |
| Guillaume Bouhours | Biomerieux SA | 47 | |
| Timothy Oostdyk | Eurofins Scientific SE | N/A | |
| Pierre Boulud | Biomerieux SA | 52 | |
| Martin Zouhar | SEB SA | N/A | |
| John Mackay | Sartorius Stedim Biotech | 61 | |
| Petra Kirchhoff | Sartorius Stedim Biotech | 54 | |
Management Performance
| Return On Equity | -0.27 | |||
| Return On Asset | -0.11 |
Neovacs SA Leadership Team
Elected by the shareholders, the Neovacs SA's board of directors comprises two types of representatives: Neovacs SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neovacs. The board's role is to monitor Neovacs SA's management team and ensure that shareholders' interests are well served. Neovacs SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neovacs SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alexandre Courtoux, Adm Director | ||
| Pr Zagury, Chairman Founder | ||
| Valerie Salentey, Head of Regulatory Affairs | ||
| Hugo Brugiere, GM Chairman | ||
| Charlene Masson, Co Relations | ||
| Vincent Serra, Chief Scientific Officer |
Neovacs Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Neovacs SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.27 | |||
| Return On Asset | -0.11 | |||
| Operating Margin | (620.28) % | |||
| Current Valuation | (30.4 M) | |||
| Shares Outstanding | 590.99 M | |||
| Price To Earning | (1.94) X | |||
| Price To Book | 0.01 X | |||
| Price To Sales | 24.75 X | |||
| Revenue | 22.59 K | |||
| Gross Profit | (4.54 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Neovacs Stock Analysis
When running Neovacs SA's price analysis, check to measure Neovacs SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neovacs SA is operating at the current time. Most of Neovacs SA's value examination focuses on studying past and present price action to predict the probability of Neovacs SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neovacs SA's price. Additionally, you may evaluate how the addition of Neovacs SA to your portfolios can decrease your overall portfolio volatility.